dual gip/glp-1 receptor agonist The Sustained Effects of a Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Tirzepatide's Unique Mechanism of Action

In an animal study, using a mouse model with different age groups, non-alcoholic steatohepatitis (NASH) was induced, revealing age-dependent effects on cardiac function

The population in SELECT was different that STEP-1 and SUMOUNT 1, with 90.1% of patients on lipid-lowering therapy and a much lower baseline LDL-C of 78 mg/dL compared to 111 mg/dL and 110 mg/dL in STEP-1 and SURMOUNT 1 respectively [33, 35, 48]

GLP-1 drugs are already changing how we treat obesity-related comorbidities

The peptide stack calculator on SeekPeptides can help you explore how different compounds interact, though any combination protocol should be developed with a qualified healthcare provider